2型糖尿病、治愈性治疗与中高危局限性前列腺癌男性生存的关联
基于瑞典前列腺癌数据库(PCBaSe),比较2210例合并2型糖尿病(T2DM)与23071例无T2DM的中高危局限性前列腺癌男性接受治愈性治疗的情况及生存。合并T2DM者接受治愈性治疗的可能性较低(OR 0.78,95%CI 0.69-0.87);合并T2DM的高危前列腺癌男性中,接受治愈性治疗者8年总生存率为79%,未接受者为33%。
要点
- 合并T2DM的中高危局限性前列腺癌男性接受治愈性治疗的OR为0.78(95%CI 0.69-0.87)。
- 合并T2DM的高危前列腺癌男性中,接受治愈性治疗者8年总生存率为79%,未接受者为33%。
- 部分生存差异反映选择偏倚,即最健康的患者接受了治愈性治疗。
核心结论
- 合并T2DM的局限性中高危前列腺癌男性接受治愈性治疗的可能性较低。
- 合并T2DM的高危前列腺癌男性中,接受治愈性治疗者生存时间显著高于未接受者,但部分生存差异反映选择偏倚。
- 临床医生应谨慎解读这些数据,确保合并T2DM的前列腺癌患者既不被治疗不足也不被治疗过度。
研究设计与样本
- 使用瑞典前列腺癌数据库(PCBaSe)数据,比较合并T2DM的前列腺癌男性(n=2210)与仅患前列腺癌的男性(n=23071)。
- 所有男性均为2006年1月1日至2014年12月31日期间诊断的中危(T1-2、Gleason评分7和/或PSA 10-20 ng/mL)或高危(T3和/或Gleason评分8-10和/或PSA 20-50 ng/mL)局限性前列腺癌。
- 采用多因素logistic回归计算合并与不合并T2DM男性接受治愈性治疗的OR。
- 计算随访至8年的总生存率,分别针对仅合并T2DM的男性和合并T2DM与前列腺癌的男性。
主要发现
- 合并T2DM的男性接受前列腺癌治愈性治疗的OR为0.78(95%CI 0.69-0.87),低于无T2DM者。
- 合并T2DM的高危前列腺癌男性中,接受治愈性治疗者8年总生存率为79%,未接受者为33%。
临床怎么用
- 临床医生应谨慎解读这些数据,确保合并T2DM的前列腺癌患者既不被治疗不足也不被治疗过度(作者建议)。
局限性
- 部分生存差异反映选择偏倚,即最健康的患者接受了治愈性治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa. SUBJECTS AND METHODS: The Prostate Cancer database Sweden (PCBaSe) was used to obtain data on men with T2DM and PCa (n = 2210) for comparison with data on men with PCa only (n = 23 071). All men had intermediate- (T1-2, Gleason score 7 and/or prostate-specific antigen [PSA] 10-20 ng/mL) or high-risk (T3 and/or Gleason score 8-10 and/or PSA 20-50 ng/mL) localized PCa diagnosed between 1 January 2006 and 31 December 2014. Multivariate logistic regression was used to calculate the odds ratios (ORs) for receipt of curative treatment in men with and without T2DM. Overall survival, for up to 8 years of follow-up, was calculated both for men with T2DM only and for men with T2DM and PCa. RESULTS: Men with T2DM were less likely to receive curative treatment for PCa than men without T2DM (OR 0.78, 95% confidence interval 0.69-0.87). The 8-year overall survival rates were 79% and 33% for men with T2DM and high-risk PCa who did and did not receive curative treatment, respectively. CONCLUSIONS: Men with T2DM were less likely to receive curative treatment for localized intermediate- and high-risk PCa. Men with T2DM and high-risk PCa who received curative treatment had substantially higher survival times than those who did not. Some of the survival differences represent a selection bias, whereby the healthiest patients received curative treatment. Clinicians should interpret this data carefully and ensure that individual patients with T2DM and PCa are not under- nor overtreated.
引用
- Crawley D, Garmo H, Rudman S, et al. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer. BJU Int. 2017. PMID: 28418195. doi:10.1111/bju.13880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。